RankAlpha logo
Back to Rankings

PRTA

ProthenaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
PRTA has unusually strong balance-sheet support for a company of its size: year-end 2025 cash was $308.4 million, 2026 year-end cash guidance was about $255 million before additional partner milestones, and the March Novo milestone plus buyback authorization improve the capital-allocation story [#IR-2026-02-19] [#IR-2026-03-09] [#8-K-2026-02-27].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.2.
What can break
PRX019 advancement could be delayed or declined by Bristol Myers Squibb.
Momentum
16
Value
41
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $16.00 · Bear $7.25
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $21.40
Why
Momentum16 · Δ7d -0.7
Value41 · Δ7d +0.0
Sentiment82 · Δ7d +3.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
16
26% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
+2.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
82
34% active weight
Current posture
7d trendImproving
Δ7d
+3.2
Δ21d
+16.4
Why this grade

Composite grade D. Momentum 16.4 / Value 41.1 / Sentiment 82.1

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$453.9M
Beta
-0.11
Shares Out
52.35M
P/E (TTM) · Derived
-1.9
P/S (TTM)
41.56
P/FCF (TTM) · Derived
-5.38
Rev YoY
+1706.4%
EPS YoY
-154.1%
Gross Margin
+93.6%
Op Margin
-2166.4%
Net Debt
-$299.16M
Current Ratio
10.43
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology